Medical Science Liaison Job Satisfaction 2009
TABLE OF CONTENTS
Medical Science Liaison Recruitment and Retention 3
Demographics, How important is salary to job satisfaction, How important is career path such as MSL levels to job satisfaction, How important is career path such as support for other jobs within the organization to job satisfaction, How important are the tools to do your job, How important is your territory size to job satisfaction, How important is the percentage of your travel to job satisfaction? 12
4 Domains of MSL Job Satisfaction 15
2009 MSL Job Satisfaction Trends 17
Confessions of a Laid-Off Liaison 19
Tick, Tock: Month 8 and Counting, Staying Motivated, Life as a Laid-Off MSL 23
Special Issue on Medical Science Liaison (MSL) Career Development
Includes handout of a 2006 Survey of 15 Senior Level MSLs on the challenges of career development and overall job satisfaction. Feature articles: 10 Ways to Grow as a Medical Science Liaison professional and Developing MSLs across a Tenure Spectrum. Authors: Michael Chandler, Jane Chin PhD.
TABLE OF CONTENTS
10 Ways to Grow as a Medical Science Liaison Professional
Developing Medical Science Liaisons across the Tenure Spectrum 11
New Hire Medical Science Liaisons: 0 to 2 Years 11
Experienced Medical Science Liaisons: 2 to 5 Years 12
Experienced Medical Science Liaisons: 5 to 10 Years 14
CAREER DEVELOPMENT OF SR. MSLS 16
MSL Training and Business Acumen
Special Issue on Medical Science Liaison (MSL) Training and Business Acumen. Includes handout of 4-Box Model of Critical 8 Questions all MSLs Must Answer. Authors: Heather Morrow PhD, Tobin Chettiath PharmD, Daniel Snyder PhD, Jane Chin PhD.
TABLE OF CONTENTS
Changing Tides: Why We Need Medical Science Liaison Training Platforms 3
Four Training Areas for MSLs 4
Assessment Scorecards 6
Advanced Training Sustains Success 8
Developing a Pharmaceutical Business Acumen 9
MSLs: The Medical Community’s Eyes and Ears 11
Financial Awareness 13
Strategic Clinical Objectives Planning 13
Compliance and the Notion of MSL Influence 14
The Pursuit of Work-Life Balance 15
Extra: What Does “Business Acumen” Mean to You? 17
Role of the Clinical Trial Liaison (CTL)
A white paper by Brian Best, Senior Director of Clinical Affairs of a Specialty Pharmaceutical Company, to discuss the role of the Clinical Trial Liaison (CTL) and the benefits that this field-based position may offer to the clinical trial sponsor, to clinical operations, and to study site personnel.
Cost of Clinical Trials 3
Opportunity for a Novel Field-Based Clinical Role 4
A Case for Implementation of CTL Program 5
Clinical Study Activity and Attention: Unmet Need 7
Specific Functions of a Clinical Trial Liaison 8
Measuring the Impact of the CTL Role 10
Clinical Trial Liaisons: A Worthwhile Investment 12
Additonal Benefits of a CTL Program 13
Complementation of the CTL Program with the MSL Program 14
Clinical Trial Liaison Role: Lessons Learned
Brian Best provided an update on real-world examples of the clinical trial liaison (CTL) team utility and reviewed challenges associated with the creation and implementation of a CTL group in a drug development organization. Major obstacles included turf wars between the CTL team and the MSL and CRA teams. Includes a point/counter-point editorial by Jane Chin, Ph.D. First Published March 2008.
Implementing CTL Program at a Specialty Pharma Company 4
CTL Turf Wars with the CRA and MSL Groups 5
Senior Leadership Endorsement 5
Help Clinical Operations Think Outside the Box 6
Debunking MSLs’ Misperception of the CTL Role 7
POINT/COUNTERPOINT: AN INEVITABLE CTL-MSL TURF WAR? 8
CTL v. MSL: The Difference is in Roles and Responsibilities 8
Semantics or True Differentiation between CTL and MSL Roles? 8
Executive Sponsorship Required for Success 9
A Personal Example 10
Medical Science Liaison Roles: Enigma and Dilemma
Second (Winter 2009) update of “Medical Science Liaison: Examining the Role, Revisited” by Jane Chin PhD, originally published in Medical Science Liaison Quarterly, Volume I Number 4, Winter 2004. Supersedes update published in Fall 2006.
“This article remains as pertinent as ever for MSL directors to read and re-read especially considering the repercussions of the 2009 PhRMA code. Compliance officers should make this a required reading.” MSL Director, Specialty Pharmaceutical Company.
A Medical Science Liaison on National TV 3
Moment of Truth Assessment for MSL Directors 4
Intent of Field-Medical Involvement 4
Reach and Frequency Directives 5
Whose Quota are These, Anyway? 5
Why MSL Roles Remain an Enigma 6
How “Safe” is Organizing MSL Programs Under Medical Affairs? 7
MSL Role: Substantive or Symbolic? 9
Expanding MSL Programs: Encouraging or Concerning? 9
A Matter of Culture and Self Examination 11
Off-Label, Safe Harbors, and MSL Compliance
Quest for “Safe Harbor” 3
The FDAMA Effect 4
Where “Safe Harbor” is Not 4
What Effective Compliance Really Requires 6
References 7
[Note: This purchase comes with a complimentary 30 minute consult with MSL Institute]
Mitigating Off-Label Risk, OIG Scrutiny of MSL Role
“Mitigating MSL Compliance Risk and Off-Label Prosecutions.” Reprint series from MSL Quarterly 2007 on MSL Compliance. Based on an Industry Conference Report by Tanya Douglas-Holland MD.
Mitigating Off-Label Risk, OIG Scrutiny of MSL Role 3
Latest Developments in Off-Label Prosecution 3
Mitigating the Risk of Private Lawsuits for Off-Label Uses 4
Role of Office of Inspector General’s (OIG) in Monitoring Off-Label Activity and Promotion 6
Importance of Integrating Federal Trade Commission (FTC) Guidelines into a Corporate Compliance program 7
Dissemination of Off-Label Information within Frameworks of Current Case Laws, FDA Rules, and Company Policies 7
Definition of a Medical Science Liaison (MSL) Role and Evaluation of MSL Risk Tolerance Level 8
Conclusion 11
MSL Metrics Consensus: MSL Activities and Metrics
“A Medical Science Liaison Metrics Consensus: Identifying Unique Field-Medical Contributions and Compliant Metrics”. Reprint series from MSL Quarterly 2007 on MSL Metrics.
Phase-Specific Measurement of Field-Based Medical Science Contribution 6
“Early Commercialization” Phase II and Phase III 6
Metrics based on Therapeutic Insight and Clinical Site Recommendations 7
Metrics based on Advocacy Leadership 7
“Commercialization” Phase IV and Product Launch 7
Metrics based on Satisfaction Scores, Quality of Scientific Exchange, and Competitive Intelligence 7
Metrics based on Investigator-Initiated Trial Program Activities 9
Justifying Field Medical Investment in Preclinical- and Phase I Development 9
Criticisms of Reach-and-Frequency Metrics 10
